Skip to main content
IMMUPHARMA PLC logo

IMMUPHARMA PLC — Investor Relations & Filings

Ticker · IMM ISIN · GB0033711010 LEI · 213800VZKGHXC7VUS895 IL Professional, scientific and technical activities
Open in API
Filings indexed 443 across all filing types
Latest filing 2019-12-19 Regulatory Filings
Country GB United Kingdom
Listing IL IMM

About IMMUPHARMA PLC

https://www.immupharma.co.uk/

ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The company's primary focus is on creating novel treatments for serious medical conditions with significant unmet needs. Its core activities involve advancing a pipeline of drug candidates through research and various stages of clinical development, leveraging its expertise in peptide technology.

Recent filings

Filing Released Lang Actions
Admission today to trading on Euronext Growth
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated 19 December 2019. The content announces that ImmuPharma PLC is commencing trading on Euronext Growth Brussels and mentions this is a 'dual listing'. It explicitly states, 'This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR")' and concludes with the standard disclaimer: 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This structure and explicit reference to RNS strongly indicate a general regulatory announcement that does not fit into the more specific categories like 10-K, ER, or DIV. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (6224 chars) is substantial enough that it is not merely an announcement *about* a report, but the report itself, which in this case is a regulatory disclosure.
2019-12-19 English
Publication of Information Note (Euronext Growth)
Regulatory Filings Classification · 1% confidence The document is an official announcement disseminated via RNS (RNS Number : 0455X) from ImmuPharma PLC on December 17, 2019. The primary purpose of the announcement is to state that the company has 'published the Information Note, as required by the Euronext Growth Market Rules Book and Belgian financial regulations' in advance of its dual listing. The document explicitly states that the Information Note is available on the website and includes an Appendix containing financial data (Consolidated Statement of Cashflows and Capitalisation Statement) related to a period subsequent to the Interim Results. Since the document itself is an announcement *about* the publication of a required regulatory/listing document (the Information Note) and includes key financial tables as an appendix, it fits the definition of a general regulatory announcement or a report publication announcement. Given that the core action is announcing the publication of a specific required document ('Information Note') related to a listing event, and it contains financial data, it is best classified as a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Because it explicitly announces the publication of a specific document ('Publication of Information Note'), RPA is a strong candidate. However, since the content is a formal regulatory disclosure via RNS, and the 'Information Note' itself is a specific type of disclosure not explicitly listed (but related to listing/financing), RNS serves as the appropriate general regulatory fallback or RPA. Given the structure—announcing the publication of a required document and providing key financial excerpts—RPA (Report Publication Announcement) is highly appropriate, as it signals the release of a larger report. I will select RPA as it directly addresses the action described in the text ('Publication of Information Note').
2019-12-17 English
Dual Listing on Euronext Growth Brussels
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated 13 December 2019. The content announces that ImmuPharma PLC's shares will be admitted to trading on Euronext Growth Brussels (a dual listing). This is a formal announcement regarding a change in the company's listing status, which is a type of corporate action or regulatory update. Since it is a formal announcement disseminated via the RNS system and concerns a significant corporate event (dual listing), it fits best under the general 'Regulatory Filings' category (RNS) as it is not a specific financial report (10-K, IR, ER) or a management/board change (MANG). It is not a capital raise (CAP) but a listing event. RNS is the most appropriate general regulatory announcement code.
2019-12-13 English
Share Price Volatility
Regulatory Filings Classification · 1% confidence The document is identified by the 'RNS Number' header and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' RNS filings are general regulatory announcements. The content addresses share price volatility and confirms the company is adequately funded, denying rumors of a fundraising. This type of market-sensitive, non-standard announcement that doesn't fit into specific categories like ER, 10-K, or DIV is best classified as a general Regulatory Filing (RNS). The document length is short (2681 chars), but it is a direct announcement, not an announcement *of* another report, so RPA is less appropriate than RNS for this specific content type.
2019-12-11 English
IMMUPHARMA TO PRESENT AT BIOTECH SHOWCASET 2020
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated December 3, 2019. The content announces that ImmuPharma PLC will be presenting at the 'Biotech Showcase™ 2020' conference. This is a communication about a future corporate event and investor engagement, not a full financial report (like 10-K or IR) or a specific regulatory filing like a Director's Dealing or Dividend Notice. The document explicitly mentions 'RNS REACH 3 December 2019' and concludes with information about RNS, which is the news service of the London Stock Exchange. Since the announcement is about an investor presentation/conference attendance, it fits best under Investor Presentation (IP). However, given the context that it is distributed via RNS and is an announcement of participation in an external event, it could also be considered a general Regulatory Filing (RNS) or an announcement related to investor relations. Since the core subject is the presentation itself, IP is a strong candidate. But, looking at the definitions, this is a general announcement distributed via the RNS system about an upcoming investor event, which often falls under the broader 'Regulatory Filings' (RNS) if it doesn't fit a more specific category like ER or DIV. Since the document is an announcement of participation in an investor conference, and not the presentation material itself, and it is distributed via RNS, I will classify it as RNS as it is a general regulatory news service announcement.
2019-12-03 English
TR-1: notification of major holdings
Major Shareholding Notification Classification · 1% confidence The document is explicitly labeled with "RNS Number : 2427V" and contains the standard format for a "TR-1: Standard form for notification of major holdings". This form is used to report changes in significant share ownership, which directly corresponds to the definition of Major Shareholding Notification. Although it is distributed via RNS (London Stock Exchange news service), the core content is a specific regulatory filing type concerning share ownership thresholds, making 'MRQ' (Major Shareholding Notification) the most accurate classification over the general 'RNS' fallback. The document details the percentage change in voting rights for 'Lanstead Capital Investors LP'.
2019-12-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.